In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor

Experimental Neurology

Volumn 225, Issue 2, 2010, Pages 320-327

  Sheng, Jian Rong ^a   Grimme, Steve ^b   Bhattacharya, Palash ^a   Stowell, Michael H B ^c   Artinger, Michael ^b   Prabahakar, Bellur S ^a   Meriggioli, Matthew N ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Nanodisc Inc   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Acetylcholine receptor; Immunoadsorption; Myasthenia gravis; Nanodisc

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; NANODISC; PHOSPHOLIPID; SCAFFOLD PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG PURIFICATION; DRUG SYNTHESIS; FEMALE; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; TORPEDO CALIFORNICA; ADSORPTION; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; SKELETAL MUSCLE; TISSUE SCAFFOLD; TORPEDO;

ADSORPTION; ANIMALS; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; TISSUE SCAFFOLDS; TORPEDO;

EID: 77956449352     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.07.003     Document Type: Article

References (41)

1. Bayburt T.H., Sligar S.G. Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers. Protein Sci. 2003, 12:2476-2481.
2. Bayburt T.H., Grinkova Y.V., Sligar S.G. Assembly of single bacteriorhodopsin trimers in bilayer Nanodiscs. Arch. Biochem. Biophys. 2006, 450:215-222.
3. Bayburt T.H., Leitz A.J., Xie G., Oprian D.D., Sligar S.G. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. J. Biol. Chem. 2007, 282:14875-14881.
4. Berman P.W., Patrick J. Experimental myasthenia gravis: a murine system. J. Exp. Med. 1980, 151:204-223.
5. Bhattacharya P., Grimme S., Ganesh B., Gopisetty A., Sheng J.R., Martinez O., Jayarama S., Artinger M., Meriggioli M., Prabhakar B.S. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J. Virol. 2010, 84:361-371.
6. Billiau A., Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukocyte Biol. 2001, 70:849-860.
7. Boldog T., Grimme S., Li M., Sligar S.G., Hazelbauer G.L. Nanodiscs separate chemoreceptor oligomeric states and reveal their signaling properties. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:11509-11514.
8. Boldog T., Li M., Hazelbauer G.L. Using Nanodiscs to create water-soluble transmembrane chemoreceptors inserted in lipid bilayers. Methods Enzymol. 2007, 423:317-335.
9. Borch J., Hamann T. The Nanodisc: a novel tool for membrane protein studies. Biol. Chem. 2009, 390:805-814.
10. Chiu H.C., Chen W.H., Yeh J.H. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther. Apher. 2000, 4:291-295.
11. Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., Spitler L.E. Plasmaphereses and immunosuppressive drug therapy in myasthenia gravis. N Engl J. Med. 1977, 297:1134-1140.
12. Denisov I.G., Grinkova Y.V., Lazarides A.A., Sligar S.G. Directed self-assembly of monodisperse phospholipid bilayer Nanodiscs with controlled size. J. Am. Chem. Soc. 2004, 126:3477-3487.
13. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 1977, 52:267-280.
14. Fischer H.C., Chan W.C.W. Nanotoxicity: the growing need for in vivo study. Curr. Opin. Biotechnol. 2007, 18:565-571.
15. Gajdos P., Chevret S., Clair B., Tranchant C., Chastang C. Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia gravis Myasthenia Gravis Clinical Study Group. Ann. Neurol. 1997, 41:789-796.
16. Gregorian S.K., Clark L., Heber-Katz E., Amento E.P., Rostami A. Induction of peripheral tolerance with peptide-specific anergy in experimental autoimmune neuritis. Cell. Immunol. 1993, 150:298-310.
17. Grob D., Simpson D., Mitsumoto H., Hoch B., Mokhtarian F., Bender A., Greenberg M., Koo A., Nakayama S. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995, 45:338-344.
18. Guo C.Y., Li Z.Y., Xu M.Q., Yuan J.M. Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum. J. Immunol. Meth. 2005, 303:142-147.
19. Hoedemaekers A.C., van Breda Vriesman P.J., De Baets M.G. Myasthenia gravis as a prototype autoimmune receptor disease. Immunol. Res. 1997, 16:341-354.
20. Jambou F., Zhang W., Menestrier M., Klingel-Schmitt I., Michel O., Caillat-Zucman S., Aissaoui A., Landemarre L., Berrih-Aknin S., Cohen-Kaminsky S. Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis. J. Clin. Invest. 2003, 112:265-274.
21. Leitz A.J., Bayburt T.H., Barnakov A.N., Springer B.A., Sligar S.G. Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology. Biotechniques 2006, 40:601-602.
22. Lindstrom J.M. Acetylcholine receptors and myasthenia. Muscle Nerve 2000, 23:453-477.
23. Luo J., Taylor P., Losen M., de Baets M.H., Shelton G.D., Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J. Neurosci. 2009, 29:13898-13908.
24. Meriggioli M.N., Sanders D.B. Myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-490.
25. Nath A., Atkins W.M., Sligar S.G. Application of phospholipid bilayer Nanodiscs in the study of membranes and membrane proteins. Biochemistry 2007, 46:2059-2069.
26. Notkins A.L., Onodera T., Prabhakar B.S. Virus-induced autoimmunity. Concepts in viral pathogenesis 1984, 210-215. Springer-Verlag, New York. A.L. Notkins, M.B.A. Oldstone (Eds.).
27. Psaridi-Linardki L., Mamlaki A., Remoundos M., Tzartos S.J. Expression of soluble ligand- and antibody-binding extracellular domain of human acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J. Biol. Chem. 2002, 277:26980-26986.
28. Psaridi-Linardki L., Trakas N., Mamlaki A., Tzartos J. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. J. Neuroimmunol. 2005, 159:183-191.
29. Ptak J., Lochman J. Imunoadsorption therapy and complement activation. Transfus. Apher. Sci. 2005, 32:263-267.
30. Sahashi K., Engel A.G., Linstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 1978, 37:212-223.
31. Seybold M.E. Plasmapheresis in myasthenia gravis. Ann. N.Y. Acad. Sci. 1987, 505:584-587.
32. + regulatory T cells. J. Immunol. 2006, 177:5296-52306.
33. Sheng J.R., Li L., Ganesh B.B., Prabhakar B.S., Meriggioli M.N. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia. Clin. Immunol. 2008, 128:172-180.
34. Tang H., Braley-Mullen H. Intravenous administration of deaggregated mouse thyroglobulin suppresses induction of experimental autoimmune thyroiditis and expression of both Th1 and Th2 cytokines. Int. Immunol. 1997, 9:679-687.
35. Tarnopolsky M.A., Bourgeois J.M., Snow R., Keys S., Roy B.D., Kwiecien J.M., Turnbull J. Histological assessment of intermediate and long-term creatine monohydrate supplementation in mice and rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R762-R769.
36. Tierney M.L., Osborn K.E., Milburn P.J., Stowell M.H., Howitt S.M. Phylogenetic conservation of disulfide-linked, dimeric acetylcholine receptor pentamers in southern ocean electric rays. J. Exp. Biol. 2004, 207:3581-3590.
37. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. Mol. Biol. 2005, 346:967-989.
38. Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol. Scand. Suppl. 2006, 183:1-7.
39. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet 2001, 357:2122-2128.
40. Wang Z.Z., Hardy S.F., Hall Z.W. Assembly of the nicotinic acetylcholine receptor. J. Biol. Chem. 1996, 271:27575-27584.
41. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2001, 15(Unit 15):8.